PF-3635659 (PF-03635659) is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist with Ki of 0.2 nM, shows potential for the treatment of chronic obstructive pulmonary disease (COPD)..

PF-232798 (PF-00232798) is a potent CCR5 antagonist with IC50 of <0.1 nM in gp160 fusion assay, exhibits potent broad-spectrum anti-HIV-1 activity.

PF-219061 (PF 219061, PF219061) is a potent, selective agonist of dopamine D3 receptor with EC50 of 8 nM.

PF-184298 is a potent, selective dual serotonin and noradrenaline monoamine reuptake inhibitor (SNRI) with IC50 of 6 nM and 21 nM, respectively.

PF-152 is a potent, highly selective and orally bioavailable MMP13 inhibitor with Ki of 1.5 nM, with no activity against MMP3 (Ki>10 uM).

PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay.

PF-06815189 is a potent, selective phosphodiesterase 2 (PDE2) inhibitor with IC50 of 0.4 nM, >1,000-fold selectivity over PDE5.

PF-06807656 is a potent, selective renal outer medullary potassium channel (ROMK, Kir1.1a) inhibitor with IC50 of 61 nM for hROMK in patch-clamp assays.

PF-06795071 is a potent, selective, covalent Monoacylglycerol Lipase (MAGL) inhibitor with IC50 of 3 nM, >1,000-fold selectivity over FAAH.

PF-06751979 is a potent, selective, brain penetrant BACE1 inhibitor with binding IC50 of 7.3, 27-fold selectivity over BACE2.

PF-06679142 is a novel potent, orally active, α1β1γ1/α2β1γ1-isoform selective AMPK activator with Kd of 14 nM, EC50 of 22 nM for α1β1γ1-AMPK, shows minimal activity at the β2-containing isoforms (α1β2γ1, α2β2γ1, α2β2γ3).

PF-06651600 malonate is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2.

PF-05661014 is a potent, selective Nav1.3 inhibitor with IC50 of 0.26 uM, shows no activity for Nav1.7 (IC50>10 uM).

PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease..

PF-04991532 (PF4991532) is a potent, hepatoselective Glucokinase (GK) activator with EC50 of 90±45 nM.

PF-04958242 is a novel potent, selctive, and orally-active AMPA receptor (AMPAR) positive allosteric modulator (PAM) with Ki of 170 nM, EC50 of 370 nM.

PF-04895162 (ICA-105665, PF 4895162) is an orally available agonist of neuronal Kv7 potassium channel, opens Kv7.2/7.3 and Kv7.3/7.5 potassium channels, also known as KCNQ2/3 and KCNQ3/5 channels.

PF-04701475 is a nove positive allosteric modulator of AMPA receptor, a prototype used to explore AMPAR-mediated pharmacology in vivo..

PF-04677490 is a potent, selective PDE1 inhibitor with IC50 of 21 nM for PDE1B.

PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. .

PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist for the treatment of diabetic nephropathies and diabetic macular oedema. .

PF-04531083 (PF 4531083) is a potent and selective, orally available sodium channel Nav1.8 blocker for treatment of pain. .

PF-04449613 (PF04449613) is a potent and selective inhibitor of PDE9..

PF-04308515 (PF 4308515) is a potent glucocorticoid receptor (GR) agonist with anti-inflammatory activity..

PF-04191834 (PF-4191834) is a potent, non‐iron chelating, non‐redox, selective and competitive inhibitor of 5-lipoxygenase (5‐LO) with Ki of 10 nM.

PF-03882845 is highly potent, selective, nonsteroidal, orally bioavailable Mineralocorticoid receptor antagonist with IC50 of 4.5 nM.

PF-03814735 is a novel, potent, orally bioavailable, reversible small-molecule Aurora kinase inhibitor with IC50 of 0.8, 5, 10 and 22 nM for Aurora A, Aurora B, Flt 1 and FAk, respectively.

PF-03654764 (PF 3654764) is a potent, selective, orally bioactive antagonist of H3 receptor with Ki of 1.4 nM.

PF-03654746 (PF 3654746) is a potent, selective, orally bioactive antagonist of H3 receptor with Ki of 2.3 nM.

PF-03463275 (PF 3463275) ia an orally bioavailable, centrally penetrant, potent, reversible, selective, and competitive inhibitor of the human GlyT1 transporter with Ki of 13 nM.